on Tharimmune Inc. (NASDAQ:THAR)
Tharimmune to Present Key Findings at Upcoming Conferences
Bridgewater-based Tharimmune, Inc., a company at the forefront of biotechnology focusing on inflammation and immunology therapies, has announced its participation in two significant conferences. At the American College of Gastroenterology Annual Scientific Meeting in Philadelphia, Chief Medical Advisor Nir Barak, M.D., is set to present Phase 1 trial results for TH104, a promising treatment for cholestatic liver disease and associated pruritus. The presentation will occur on October 28, 2024.
Randy Milby, the CEO, will address the 2024 ThinkEquity Conference in New York, sharing insights and engaging with investors. This session will be webcast live on October 30, 2024, with a replay available for 90 days. The participation in these events aims to highlight Tharimmune’s advancements and foster investor interest.
R. P.
Copyright © 2024 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all Tharimmune Inc. news